ASH: Sanofi, Johnson & Johnson on collision course with Sarclisa, Darzalex 4-drug regimens in myeloma

Sanofi and Johnson & Johnson are adding more fuel to their CD38 rivalry fire between Sarclisa and Darzalex in multiple myeloma. With approvals already in place as triplet therapies, the two companies are now touting early clinical wins for four-drug regimens.